Apimeds Pharmaceuticals US APUS
NYSE APUS
$3.10 -0.10 (-3.13%)
At close: Oct 22, 2026 · 4:00 PM EDT

Apimeds Pharmaceuticals US (APUS) Cash & Equivalents (2023 - 2026)

Updated

Apimeds Pharmaceuticals US's Cash & Equivalents was $278,371 in Q2 2026, down 96.8% from $8.74 million a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) Cash & Equivalents (2023 - 2026) Analysis & Trends

At the end of FY2025, Cash & Equivalents at Apimeds Pharmaceuticals US came in at $1.64 million.

  • In earlier years, Cash & Equivalents was $3,455 in FY2024 (-99.2%) and $410,481 in FY2023.
  • The Q2 2026 figure marks the lowest quarterly Cash & Equivalents since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn 16.91 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn 6.57 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn 6.85 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn 4.90 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn 3.18 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn 976.00 Mn
10 Apimeds Pharmaceuticals US 4.68 Mn -14.96 Mn - 278,371.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 278,371.00
Dec 31, 2025 1.64 Mn
Sep 30, 2025 6.99 Mn
Jun 30, 2025 8.74 Mn
Mar 31, 2025 250,342.00
Dec 31, 2024 3,455.00
Dec 31, 2023 410,481.00
API Access

Apimeds Pharmaceuticals US Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=APUS&period=max&api_key=YOUR_API_KEY